HIGHOutside partyCounterparty
Jazz
“10-K Item 1A: 'We depend on Jazz to develop and commercialize zanidatamab in the territories covered by the Amended Jazz Collaboration Agreement'”
ZYME · Concentration risk · 10-K extracted
Zymeworks (ZYME) concentration risks
Updated
The most significant concentration Zymeworks discloses is Jazz, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Zymeworks’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHBuilt-in & outside partyProduct / Revenue mix
zanidatamab (Ziihera)
“10-K Item 1A: 'We have only one product approved for commercial sale...other than the receipt of royalties relating to sales of zanidatamab'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is defined by two interlocking high-share dependencies that together determine virtually all near-term commercial prospects. The company has only one product approved for commercial sale, zanidatamab (Ziihera), a large high-share exposure by disclosed size with a mixed structural-and-idiosyncratic character. The structural dimension is that single-asset biopharmaceutical companies necessarily rely on one product for commercial revenue; the idiosyncratic dimension is that any setback — safety signal, label restriction, competitive displacement, or reimbursement challenge — would have no offsetting commercial portfolio to absorb the impact. Layered directly on that product concentration is a counterparty dependency: the company depends on Jazz to develop and commercialize zanidatamab in the territories covered by the Amended Jazz Collaboration Agreement — also a high-share dependency by disclosed size. Jazz controls the commercialization engine for the product in those territories, meaning that the company's royalty and milestone economics are mediated through a single strategic partner's execution, prioritization decisions, and commercial investment choices. Underperformance by Jazz in its territories would directly constrain the revenue potential of the only approved asset. The two exposures compound each other: a single commercial product developed predominantly through a single external partner creates a risk structure where both product-level and counterparty-level shocks converge on the same financial outcome. Monitoring zanidatamab uptake data, Jazz's commercial execution, and any pipeline progression that could diversify the product base are the primary analytical priorities for this investment profile.
For the engine’s reasoning on ZYME’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ZYME● | Zymeworks Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.